Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial

Abstract. Purpose: Cancer vaccines represent a novel treatment modality with a complementary mode of action addressing a crucial bottleneck for checkpoint inhibitor (CPI) efficacy. CPIs are expected to release brakes in T-cell responses elicited by vaccination, leading to more robust immune responses. Increased anti-tumor T-cell responses may confer increased anti-tumor activity in patients with…

Read the full article here

Source: American Association for Cancer Research

Categories: Hem/Oncs, Latest Headlines

Tweets with this article

Yousef Zakharia

Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial @MelanomaIowa @UIowaCancer @IntMedatIowa @uihealthcare https://t.co/BSLaUCyeUJ

Epigenetic Regulation for Immune Evasion in Advanced RCC | GU Oncology Now

Dr. Zakharia explains why guadecitabine plus durvalumab may be a good treatment approach in patients with advanced RCC.

Yousef Zakharia April 30, 2024

Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043

Epigenetic modulation is well established in hematologic malignancies but to a lesser degree in solid tumors. Here we report the results of a phase Ib/II…

Yousef Zakharia February 2, 2024

ASCO

Dear Colleagues,Many physicians have raised concerns about the current Maintenance of Certification (MOC) requirements administered by the American Board of Internal Medicine (ABIM). ASCO members…

Yousef Zakharia September 8, 2023

Dr. Yousef Zakharia: “I Believe in Teamwork”

Dr. Yousef Nabih Zakharia’s journey from Syria to the heart of Iowa, his dedication to his patients, and his unwavering commitment to advancing kidney cancer…

Yousef Zakharia September 7, 2023

The world’s platform for change

Change.org is the world’s largest petition platform, using technology to empower more than 200 million users to create the change they want to see.

Yousef Zakharia August 13, 2023

Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation

A genomic investigation of 3,600 small cell lung cancer (SCLC) tumors reveals novel rare cohorts with potential therapeutic importance, biopsy site–specific heterogeneity, and new insights…

Cancer Discovery July 18, 2023

Circadian Disruption and Colorectal Cancer Incidence in Black Women

AbstractBackground:. Animal and experimental studies suggest circadian disruption increases colorectal cancer risk, but evidence in humans is limited. We examined night shift work, chronotype, and…

Cancer Epidemiology, Biomarkers & Prevention July 18, 2023

Multiomic mapping of acquired chromosome 1 copy number and structural variants to identify therapeutic vulnerabilities in multiple myeloma.

Abstract. Purpose: Chromosome 1 (chr1) copy number abnormalities (CNAs) and structural variants (SV) are frequent in newly diagnosed multiple myeloma (NDMM) and associate with a…

Muzaffar Qazilbash July 18, 2023

Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)

AbstractPurpose:. Devimistat (CPI-613) is a novel inhibitor of tumoral mitochondrial metabolism. We investigated the effect of devimistat in vitro and in a phase Ib clinical…

Benjamin Weinberg, MD, FACP July 17, 2023

ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma

PI3K/Akt signaling promotes metabolic adaptation to ONC201-mediated disruption of mitochondrial energy homeostasis in diffuse intrinsic pontine glioma, highlighting the utility of a combination treatment strategy…

Cancer Research July 17, 2023

Related Articles